DANIPHARM A/S: Financial statements 2020
CVR: 12335040
Source: annual report 2020, Danish Business Authority
01/07/2019 – 30/06/2020
DANIPHARM A/S (CVR 12335040) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 91,596,524 and a net result of DKK 5,767,443 compared with DKK 16,324,503 the year before. The profit margin was 6.3%. Equity in the 2020 report amounted to DKK 26,924,469. The solvency ratio was 39.1%. The company had 22 employees in the financial year.
- Revenue
- DKK 91,596,524
- Gross Profit
- DKK 31,638,553
- Profit/Loss
- DKK 5,767,443
- Equity
- DKK 26,924,469
- Total Assets
- DKK 68,942,396
- Employees
- 22
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 91.6 mio. | 31.6 mio. | 5.8 mio. | 26.9 mio. | 22 |
| 2019 | - | 42.9 mio. | 16.3 mio. | 21.2 mio. | 21 |
| 2018 | - | 35.7 mio. | 10.2 mio. | 24.8 mio. | 22 |
| 2017 | 93.6 mio. | 37 mio. | 11.3 mio. | 50.6 mio. | 26 |
| 2016 | 85.2 mio. | 40.9 mio. | 15.2 mio. | 41.8 mio. | 22 |
Official annual report
How creditworthy is DANIPHARM A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of February 13, 2020, Svend Blankholm has left the board of directors of DANIPHARM A/S.
About DANIPHARM A/S
DANIPHARM A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 1988. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The management consists of Peter Rørvig. The board consists of Niels Ulrik Heine (chair), Helle Rørvig and Peter Rørvig. The company is owned by H&P Rørvig Holding A/S. The company has 24 employees (2018). In 2025, the company reported a gross profit of DKK 37,586,751 and a net result of DKK 13,717,304 compared with DKK 5,113,647 the year before. Equity in the 2025 report amounted to DKK 60,280,949.